Hormonal therapy of prostate cancer: Is there any news?

Urologia Internationalis

Volumn 63, Issue 1, 1999, Pages 80-85

  Pummer, Karl ^a   Schmid, Hans Peter ^b   Trummer, Harald ^a   Augustin, Herbert ^a   Hubmer, Gerhart ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Intermittent androgen suppression; Maximal androgen blockade; New concepts of hormonal therapy

Indexed keywords

ANDROGEN;

CANCER SURVIVAL; DRUG EFFICACY; HORMONAL THERAPY; HORMONE INHIBITION; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

EID: 0032742812     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030422     Document Type: Review

References (27)

1. Huggins C, Stevens RE, Hodges CV: Studies in prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1943;41:209.
2. Labric F, Dupont A, Belanger A, et al: New approaches in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 1983;4:579-594.
3. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995;45: 839-845.
4. Geller J, Albert JD, Loza D: DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978;46:440-445.
5. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
6. Denis L: Role of maximal androgen blockade in advanced prostate cancer. Prostate 1994; (suppl 5): 17-22.
7. Janknegt RA, Ahbou CC, Bartoletti R, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-82.
8. Iversen P, Christensen MG, Friis E, et al: A phase III trial ol zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990;66:1058-1066.
9. Boccardo F, Pace M, Rubagotti A, et al: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993; 29:1088-1093.
10. Tyrell CJ, Altwein JE, Klippel F, et al: Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer: Survival update. Cancer 1993;72:3878-3879.
11. Iversen P, Rasmussen F, Klarskov P, et al: Long-term results of Danish Prostatic Cancer Group Trial 86: Gosereline acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993;72:3851-3854.
12. Bertegna C, De Gery A, Hucher M, et al: Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostate cancer: A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994;73:396-402.
13. Prostate Cancer Trialist's Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-269.
14. Crawford ED, Eisenberger M, McLeod DG, et al: Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate. Results of NCI intergroup study 0105 (SWOG and ECOG) (abstr 1311). J Urol 1997; 157:336.
15. Peeling WB: Phase III studies to compare goseretin (zoladex) with orchiectomy and diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989;33:45-52.
16. Limonta P, Dondi D, Moretti RM, et al: Anti-proliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75:207-212.
17. Miller G, Rosenblum M: Growth inhibition of LNCaP cell line. 8th International Prostate Cancer Update, Beaver Creek, Jan 28-31, 1998.
18. Noble RL: Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 1997;37:82-94.
19. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr: Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-2550.
20. Vahlensieck W, Wegner G: Continuous versus intermittent oral therapy with estramustine phosphate (estracyt). Scand J Urol Nephrol 1980;(suppl 55): 147-149.
21. Trachtenberg J: Experimental treatment of prostate cancer by intermittent hormonal therapy. J Urol 1987;137:785-788.
22. Russo P, Liguori G, Heston WDW, Huryk R, Yang C-R, Fair WR, Whitmore WF, Herr HW: Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res 1987;47: 5967-5970.
23. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50: 2275-2282.
24. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD: Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 1993;71: 2782-2790.
25. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995;45: 839-845.
26. Miller JI, Ahmann FR, Drach GW, et al: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-959.
27. Hillner BE, McLeod DG, Crawford ED, Bennett CL: Estimating the cost-effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995;45:633-640.